• Molecular Partners announced preclinical results supporting advancement of MP0632 into studies needed before seeking permission for human trials.
• The T-cell engager selectively killed tumor cells, with efficacy comparable to a clinical-stage benchmark but a substantially improved preclinical safety profile.
• Testing found no detectable effects on primary human mesothelial or epithelial cells, supporting development for solid tumors co-expressing MSLN and EpCAM.
• Results will be presented Nov. 7, 2026, at the Society for Immunotherapy of Cancer conference in Phoenix.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Molecular Partners AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611060100OMX_____CNEWS_EN_GNW9871905_en) on November 06, 2026, and is solely responsible for the information contained therein.